Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Cyclophosphamide in Severe Mucous Membrane Pemphigoid
NCT03295383Phase 3Active, not recruiting
- Sponsor
- Rouen University Hospital
- Start
- Jul 2019
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in mucous membrane pemphigoid (MMP) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Proportion of patients achieving Complete Remission (CR) or Partial Remission (PR) at 12 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
mucous membrane pemphigoid (MMP)
Beyond the preview
Go deeper on NCT03295383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295383.